NKG2D/Ligand dysregulation and functional alteration of innate immunity cell populations in pediatric IBD

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1910-1922

  La Scaleia, Raffaella ^a   Stoppacciaro, Antonella ^a   Oliva, Salvatore ^a   Morrone, Stefania ^a   Di Nardo, Giovanni ^a   Santoni, Angela ^b   Cucchiara, Salvatore ^a   Palmieri, Gabriella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

T cells; CD56+ T cells; MIC A B; ULBPs

Indexed keywords

ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CROHN DISEASE; CYTOFLUOROMETRY; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; INNATE IMMUNITY; INTERFERON PRODUCTION; LEUKOCYTE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SCHOOL CHILD; T LYMPHOCYTE; ULCERATIVE COLITIS;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNITY, INNATE; INTERFERON-GAMMA; LIGANDS; LYMPHOCYTES; MALE; MONOCYTES; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROGNOSIS; RISK FACTORS; T-LYMPHOCYTES;

EID: 84866391640     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22899     Document Type: Article

References (49)

1. Fiocchi C,. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998; 115: 182-205. (Pubitemid 28307304)
2. Macdonald TT, Monteleone G,. Immunity, inflammation, and allergy in the gut. Science. 2005; 307: 1920-1925. (Pubitemid 40404695)
3. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434. (Pubitemid 47123518)
4. Mayer L,. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010; 45: 9-16.
5. Rescigno M, Di Sabatino A,. Dendritic cells in intestinal homeostasis and disease. J Clin Invest. 2009; 119: 2441-2450.
6. Mahida YR,. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000; 6: 21-33.
7. Varol C, Zigmond E, Jung S,. Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nat Rev Immunol. 2010; 10: 415-426.
8. Ng SC, Kamm MA, Stagg AJ, et al. Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation. Inflamm Bowel Dis. 2010; 16: 1787-1807.
9. Smith PD, Smythies LE, Shen R, et al. Intestinal macrophages and response to microbial encroachment. Mucosal Immunol. 2011; 4: 31-42.
10. Jabri B, Ebert E,. Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue. Immunol Rev. 2007; 215: 202-214. (Pubitemid 46212241)
11. Meresse B, Cerf-Bensussan N,. Innate T cell responses in human gut. Semin Immunol. 2009; 21: 121-129.
12. Maynard CL, Weaver CT,. Intestinal effector T cells in health and disease. Immunity. 2009; 31: 389-400.
13. Spencer J, Isaacson PG, Diss TC, et al. Expression of disulfide-linked and non-disulfide-linked forms of the T cell receptor gamma/delta heterodimer in human intestinal intraepithelial lymphocytes. Eur J Immunol. 1989; 19: 1335-1338. (Pubitemid 19196916)
14. Pittet MJ, Speiser DE, Valmori D, et al. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 2000; 164: 1148-1152. (Pubitemid 30067223)
15. Cohavy O, Targan SR,. CD56 marks an effector T cell subset in the human intestine. J Immunol. 2007; 178: 5524-5532. (Pubitemid 46674347)
16. O'Keeffe J, Doherty DG, Kenna T, et al. Diverse populations of T cells with NK cell receptors accumulate in the human intestine in health and in colorectal cancer. Eur J Immunol. 2004; 34: 2110-2119.
17. McVay LD, Li B, Biancaniello R, et al. Changes in human mucosal gamma delta T cell repertoire and function associated with the disease process in inflammatory bowel disease. Mol Med. 1997; 3: 183-203. (Pubitemid 27215285)
18. Shimamoto M, Ueno Y, Tanaka S, et al. Selective decrease in colonic CD56(+) T and CD161(+) T cells in the inflamed mucosa of patients with ulcerative colitis. World J Gastroenterol. 2007; 13: 5995-6002. (Pubitemid 350238266)
19. Kleinschek MA, Boniface K, Sadekova S, et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med. 2009; 206: 525-534.
20. Raulet DH,. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003; 3: 781-790. (Pubitemid 37328656)
21. Ogasawara K, Lanier LL,. NKG2D in NK and T cell-mediated immunity. J Clin Immunol. 2005; 25: 534-540. (Pubitemid 43011745)
22. González S, Groh V, Spies T,. Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol. 2006; 298: 121-138.
23. Upshaw JL, Leibson PJ,. NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. Semin Immunol. 2006; 18: 167-175. (Pubitemid 43817560)
24. Poggi A, Zancolli M, Boero S, et al. Differential survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells. Int J Cancer. 2011; 129: 387-396.
25. Eagle RA, Trowsdale J,. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007; 7: 737-744. (Pubitemid 47327391)
26. Champsaur M, Lanier LL,. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010; 235: 267-285.
27. Perera L, Shao L, Patel A, et al. Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis. 2007; 13: 298-307. (Pubitemid 46465911)
28. Groh V, Steinle A, Bauer S, et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science. 1998; 279: 1737-1740. (Pubitemid 28164472)
29. Eagle RA, Jafferji I, Barrow AD,. Beyond stressed self: evidence for NKG2D ligand expression on healthy cells. Curr Immunol Rev. 2009; 5: 22-34.
30. Roberts AI, Lee L, Schwarz E, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001; 167: 5527-5530. (Pubitemid 33062738)
31. Ebert EC, Groh V,. Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology. 2008; 124: 33-41. (Pubitemid 351537570)
32. Van Belle TL, von Herrath MG,. The role of the activating receptor NKG2D in autoimmunity. Mol Immunol. 2009; 47: 8-11.
33. Kjellev S, Haase C, Lundsgaard D, et al. Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur J Immunol. 2007; 37: 1397-1406. (Pubitemid 46925322)
34. Ito Y, Kanai T, Totsuka T, et al. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol. 2008; 294: G199-207.
35. Allez M, Tieng V, Nakazawa A, et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology. 2007; 132: 2346-2358. (Pubitemid 46890855)
36. Tieng V, Le Bouguénec C, du Merle L, et al. Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci U S A. 2002; 99: 2977-2982. (Pubitemid 34240571)
37. Nieuwenhuis EE, Escher JC,. Early onset IBD: what's the difference? Dig Liver Dis. 2008; 40: 12-15. (Pubitemid 350246388)
38. Bousvaros A, Morley-Fletcher A, Pensabene L, et al. Research and clinical challenges in paediatric inflammatory bowel disease. Dig Liver Dis. 2008; 40: 32-38. (Pubitemid 350246391)
39. Sauer CG, Kugathasan S,. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Gastroenterol Clin North Am. 2009; 38: 611-628.
40. Carvalho R, Hyams JS,. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg. 2007; 16: 164-171. (Pubitemid 46977778)
41. Loonen HJ, Griffiths AM, Merkus MP, et al. A critical assessment of items on the pediatric Crohn's Disease Activity Index. J Pediatr Gastroenterl Nutr. 2003; 36: 90-95. (Pubitemid 41672625)
42. Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric Ulcerative Colitis Activity Index: a prospective multicenter study. Gastroenterology. 2007; 133: 423-432. (Pubitemid 47193130)
43. Seder RA, Darrah PA, Roederer M,. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008; 8: 247-258. (Pubitemid 351432801)
44. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008; 58: 2307-2317.
45. Ehrlich LI, Ogasawara K, Hamerman JA, et al. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol. 2005; 174: 1922-1931. (Pubitemid 40223932)
46. La Scaleia R, Morrone S, Stoppacciaro A, et al. Peripheral and intestinal CD4+ T cells with a regulatory phenotype in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2010; 51: 563-572.
47. Adams DH, Eksteen B,. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol. 2006; 6: 244-251. (Pubitemid 43290993)
48. Giacomelli R, Parzanese I, Frieri G, et al. Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease. Clin Exp Immunol. 1994; 98: 83-88. (Pubitemid 24315456)
49. Frey O, Meisel J, Hutloff A, et al. Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis. Ann Rheum Dis. 2010; 69: 1495-1501.